Epidemiological studies suggest associations between diabetes mellitus and some cancers.
The risk of a number of cancers appears to be increased in diabetes mellitus. On the other …

Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …

Abstract Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L-
cells in response to nutrients. GLP-1 lowers blood glucose levels by stimulating insulin …

Controversy exists regarding the potential regenerative influences of incretin therapy on
pancreatic β-cells versus possible adverse pancreatic proliferative effects. Examination of …

Importance Acute pancreatitis has significant morbidity and mortality. Previous studies have
raised the possibility that glucagonlike peptide 1 (GLP-1)–based therapies, including a GLP …

Objective To investigate the risk of pancreatitis associated with the use of incretin-based
treatments in patients with type 2 diabetes mellitus. Design Systematic review and meta …

There is no question that incretin-based glucose-lowering medications have proven to be
effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists …

Human Islet amyloid polypeptide (hIAPP) from pancreatic β cells in the islet of Langerhans
has different physiological functions including inhibiting the release of insulin and glucagon …

Abstract Background/Aims: Pancreatogenic, or type 3c, diabetes (T3cDM) occurs due to
inherited or acquired pancreatic disease or resection. Although similar to the more prevalent …

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
are incretin hormones that control the secretion of insulin, glucagon, and somatostatin to …